[breadcrumb_custom]

Day: July 8, 2022

Rating Indicators

VERU Stock: Few Reasons To Be Better

Veru Inc. (NASDAQ: VERU) revealed the findings of phase III trials of antiviral medication for patients with severe COVID-19. In clinical studies, the sabizabulin candidate